ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma

Melanomas are characterized by activating “driver” mutations in BRAF, NRAS, KIT, GNAQ, and GNA11. Resultant mitogen-activated protein kinase (MAPK) pathway signaling makes some melanomas susceptible to BRAF (BRAF V600 mutations), MEK1/2 (BRAF V600, L597, fusions; NRAS mutations), or other kinase inh...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Hutchinson, Katherine E., Johnson, Douglas B., Johnson, Adam S., Sanchez, Violeta, Kuba, Maria, Lu, Pengcheng, Chen, Xi, Kelley, Mark C., Wang, Qingguo, Zhao, Zhongming, Kris, Mark, Berger, Michael F., Sosman, Jeffrey A., Pao, William
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2015
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4673168/
https://ncbi.nlm.nih.gov/pubmed/26084293
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados